Login to Your Account

Zealand shares dip as Boehringer passes on dual GLP drug ZP2929

By Cormac Sheridan
Staff Writer

Wednesday, January 22, 2014
Buoyed by recent progress in its alliance with Sanofi SA, investors in the Danish diabetes drug developer Zealand Pharma A/S reacted calmly to news that another partner, Boehringer Ingelheim GmbH, was terminating its interest in ZP2929, a dual-acting agonist of the glucagon and glucagon-like peptide-1 (GLP-1) receptors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription